Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 29, 2001 (52 weeks)
Business Overview: The largest distributor of healthcare products and services to office-based practitioners in North America and Europe. Operations are divided into two segments: Healthcare Distribution (dental, medical, veterinary, and international) and Technology (practice management software and value-added services). The company serves over 400,000 customers globally.
Key Financial Metrics
| Metric (in thousands) | 2001 | 2000 |
|---|---|---|
| Net Sales | $2,558,243 | $2,381,721 |
| Gross Profit | $699,324 | $647,901 |
| Gross Margin | 27.3% | 27.2% |
| Operating Income | $147,750 | $112,589 |
| Net Income | $87,373 | $56,749 |
| Diluted EPS | $2.01 | $1.35 |
| Operating Cash Flow | $190,911 | $152,994 |
| Total Debt | $261,417 | $276,693 |
| Cash & Equivalents | $193,367 | $58,362 |
| Working Capital | $489,909 | $423,547 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.4% to $2.56 billion. On a comparable basis (excluding the 53rd week in 2000), growth was 8.7%.
- Medical: Sales rose 17.0% to $929.8 million, driven by increased sales to core physician offices and alternate care markets.
- Dental: Sales rose 3.0% to $1.11 billion due to increased account penetration.
- International: Sales rose 2.1% to $398.1 million, offset by unfavorable exchange rates.
- Veterinary: Sales declined 6.5% to $52.7 million due to the loss of a product line.
- Profitability: Operating income increased 31.2% to $147.8 million. Net income increased 54.0% to $87.4 million.
- Costs: Selling, general, and administrative (SG&A) expenses increased 6.0%, but as a percentage of sales, general and administrative expenses decreased 0.3% due to restructuring efficiencies.
- Restructuring: Unlike 2000, which incurred $14.4 million in restructuring costs, 2001 had no new restructuring charges, though payments for prior accruals continued.
- Liquidity: Cash and cash equivalents increased significantly from $58.4 million to $193.4 million, driven by strong operating cash flow ($190.9 million) and reduced debt levels.
Guidance, Outlook, Risks, and Unusual Items
- Outlook & Strategy: Management anticipates continued sales growth and expects to invest over $50 million in capital projects in 2002 to modernize facilities and computer systems. The company plans to renew its $150 million revolving credit facility expiring in August 2002.
- Accounting Changes: The company is adopting FAS 141 and FAS 142 in 2002. This will eliminate goodwill amortization (estimated to increase 2002 diluted EPS by $0.17) and require annual impairment testing.
- Legal Contingencies:
- Product Liability: Defendant in approximately 72 cases, including 56 involving latex glove allergies and 9 involving "Phen/fen" drugs. The company expects indemnification from manufacturers.
- Software Litigation: A class action lawsuit regarding practice management software (Easy Dental) is pending before the Texas Supreme Court. A trial is stayed pending the court's decision.
- New Litigation: Served with a nationwide class action complaint in New Jersey in February 2002 alleging breach of contract and consumer fraud.
- Risks: Exposure to foreign currency fluctuations (hedged via forward contracts), intense competition on price, and potential impacts of healthcare reform and managed care trends.
Investor Verification Checklist
- Goodwill Impairment: Verify the impact of the new FAS 142 standard on the $288 million in goodwill and intangibles, specifically the results of the transitional impairment test required in 2002.
- Legal Exposure: Monitor the outcome of the Texas Supreme Court review regarding the Easy Dental class action and the status of the new New Jersey class action.
- Debt Maturity: Confirm the renewal of the $150 million revolving credit facility due in August 2002 and the repayment schedule for the $230 million in private placement senior notes.
- International Currency: Assess the impact of exchange rate fluctuations on the European segment, which contributed $398 million in sales but faced unfavorable translation adjustments.
- Acquisition Integration: Review the integration progress of the two acquisitions completed in 2001 and the earn-out obligations associated with the 1999 GIV acquisition.